Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

Pharmacology, Clinical Clinical Trial

Official title:
Investigation of the Pharmacokinetics, Safety, and Tolerability of Neladenoson Bialanate in Subjects With Hepatic Impairment (Classified as Child Pugh A and B) and in Age-, Weight-, and Gender-matched Healthy Subjects, Following a Single Oral Dose in a Single-center, Non-randomized, Non-controlled, Non-blinded Study

Status Terminated

Clinical Trial Summary

Neladenoson bialanate is currently under clinical development for a condition in which the heart has trouble pumping blood through the body (chronic heart failure). Liver impairment is a condition in which the liver is not working as well as they should. The goal of the study is to learn more about the safety of neladenoson bialanate, how it is tolerated and the way the body absorbs, distributes and excretes the study dug given as a single oral dose neladenoson bialanate in participants with liver impairment and healthy participants matched for age-, gender-, and weight

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Pharmacology, Clinical

Clinical Trial Details

NCT number	NCT04322253
Study type	Interventional
Source	Bayer
Contact
Status	Terminated
Phase	Phase 1
Start date	August 24, 2017
Completion date	December 17, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00941057` - Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium	Phase 1
Completed	`NCT01707407` - A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects	Phase 1
Terminated	`NCT04320771` - Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight	Phase 1
Completed	`NCT00855660` - Effect of Riociguat on Bone Metabolism	Phase 1
Completed	`NCT03929861` - Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations	Phase 1
Completed	`NCT01489488` - Relative Bioavailability and Food Effect Study	Phase 1
Completed	`NCT02394093` - To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.	Phase 1
Completed	`NCT01044524` - Study to Investigate ADME of 14C Labeled SLV334 After an i.v. Infusion	Phase 1